141 related articles for article (PubMed ID: 10086658)
41. Balancing the benefits and costs of antibiotic drugs: the TREAT model.
Leibovici L; Paul M; Andreassen S
Clin Microbiol Infect; 2010 Dec; 16(12):1736-9. PubMed ID: 20673259
[TBL] [Abstract][Full Text] [Related]
42. Antibiotic resistance in Helicobacter pylori.
Teare L; Peters T; Saverymuttu S; Owen R; Tiwari I
Lancet; 1999 Jan; 353(9148):242. PubMed ID: 9923909
[No Abstract] [Full Text] [Related]
43. Empirical or susceptibility-guided treatment for
Gisbert JP
Therap Adv Gastroenterol; 2020; 13():1756284820968736. PubMed ID: 33240392
[TBL] [Abstract][Full Text] [Related]
44. [A decision analysis model in laboratory medicine--appropriate usage of microbiological examination in women with dysuria].
Inoue Y
Rinsho Byori; 1990 May; 38(5):587-92. PubMed ID: 2199709
[TBL] [Abstract][Full Text] [Related]
45. Economic evaluations in medicine: still more questions than answers?
Grossi E
Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):347-50. PubMed ID: 9789124
[No Abstract] [Full Text] [Related]
46. Development of novel nanoparticles shelled with heparin for berberine delivery to treat Helicobacter pylori.
Chang CH; Huang WY; Lai CH; Hsu YM; Yao YH; Chen TY; Wu JY; Peng SF; Lin YH
Acta Biomater; 2011 Feb; 7(2):593-603. PubMed ID: 20813208
[TBL] [Abstract][Full Text] [Related]
47. [Decision analysis in antibiotic therapy].
Calvo MV; Domínguez-Gil A
Enferm Infecc Microbiol Clin; 1990 Apr; 8(4):199-207. PubMed ID: 2128607
[TBL] [Abstract][Full Text] [Related]
48. Helicobacter pylori eradication.
Wilcock M
Br J Gen Pract; 1997 Aug; 47(421):529. PubMed ID: 9302806
[No Abstract] [Full Text] [Related]
49. What's the use of susceptibility testing?
Greenwood D
J Chemother; 1997 May; 9 Suppl 1():7-12. PubMed ID: 9248957
[TBL] [Abstract][Full Text] [Related]
50. Drug-Resistant
Jearth V; Rath MM; Chatterjee A; Kale A; Panigrahi MK
Diagnostics (Basel); 2023 Sep; 13(18):. PubMed ID: 37761310
[No Abstract] [Full Text] [Related]
51. Best Practices for
Graham DY
Gastroenterol Hepatol (N Y); 2024 Mar; 20(3):159-168. PubMed ID: 38680170
[TBL] [Abstract][Full Text] [Related]
52. Pharmacoeconomics--determination of the cost-effectiveness of Helicobacter pylori eradication.
Curtiss FR
J Manag Care Pharm; 2003; 9(5):451-2, 455-6. PubMed ID: 14613444
[No Abstract] [Full Text] [Related]
53. What Is New in
Dore MP; Pes GM
J Clin Med; 2021 May; 10(10):. PubMed ID: 34068062
[No Abstract] [Full Text] [Related]
54. Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship.
Graham DY; Liou JM
Clin Gastroenterol Hepatol; 2022 May; 20(5):973-983.e1. PubMed ID: 33775895
[TBL] [Abstract][Full Text] [Related]
55. Culture-based antibiotic susceptibility testing for
Francesco V; Zullo A; Manta R; Satriano A; Fiorini G; Pavoni M; Saracino IM; Giostra F; Monti G; Vaira D
Ann Gastroenterol; 2022; 35(2):127-134. PubMed ID: 35479595
[TBL] [Abstract][Full Text] [Related]
56. Efficiency of Diagnostic Testing for
Rojas García P; van der Pol S; van Asselt ADI; Postma M; Rodríguez-Ibeas R; Juárez-Castelló CA; González M; Antoñanzas F
Antibiotics (Basel); 2021 Jan; 10(1):. PubMed ID: 33430005
[TBL] [Abstract][Full Text] [Related]
57. Implications of the paradigm shift in management of
Graham DY
Therap Adv Gastroenterol; 2023; 16():17562848231160858. PubMed ID: 36950252
[TBL] [Abstract][Full Text] [Related]
58. Clinical Factors Implicated in Antibiotic Resistance in
White B; Winte M; DeSipio J; Phadtare S
Microorganisms; 2022 Jan; 10(2):. PubMed ID: 35208776
[No Abstract] [Full Text] [Related]
59. What are the treatment goals for Helicobacter pylori infection?
Fennerty MB
Gastroenterology; 1997 Dec; 113(6 Suppl):S120-5. PubMed ID: 9394773
[TBL] [Abstract][Full Text] [Related]
60. Costeffectiveness of diagnostic tests.
Mushlin AI; Ruchlin HS; Callahan MA
Lancet; 2001 Oct; 358(9290):1353-5. PubMed ID: 11684235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
